Friday - November 1, 2024
ND Expert Sean Kassen: Statement on first FDA-approved treatment for Niemann-Pick Type C disease
September 20, 2024
NOTRE DAME, Indiana, Sept. 20 -- The University of Notre Dame issued the following news:

Sean Kassen, director of the Ara Parseghian Medical Research Fund at Notre Dame. (Photo by Barbara Johnston/University of Notre Dame)

Today, the FDA announced the first approved treatment for Niemann-Pick Type C (NPC) disease: an oral medication named Miplyffa (arimoclomol). Sean Kassen, director of the Ara Parseghian Medical Research Fund at the University of Notre Dame, said this . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation
Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products